Cost of Chronic Hepatitis B Infection in the United States

[Guest guest]

Cost of Chronic Hepatitis B Infection in the United States.

Journal of Clinical Gastroenterology. Chronic Hepatitis B from a Global

Perspective: Epidemiology and Costs of Illness. 38(10) Supplement

3:S144-S147, November/December 2004.

Lee, Todd A. PharmD, PhD *+++; Veenstra, L. PharmD, PhD ; Hloeje,

Uchenna H. MD, MPH [P]; Sullivan, D. PhD

Abstract:

Goals: To estimate the direct medical costs associated with chronic

hepatitis B (CHB) infection in the United States.

Background: Approximately 240,000 new cases of hepatitis B infection occur

annually in the United States. There are estimated to be 1.25 million

sufferers of CHB in the United States. However, the economic impact of these

infections has not been well studied.

Study: We conducted a retrospective cohort analysis using administrative

healthcare claims data to estimate costs for six health states associated

with CHB infection. The six states were as follows: 1) CHB, 2) compensated

cirrhosis, 3) decompensated cirrhosis, 4) liver transplantation, 5)

transplant care >12 months following transplant, and 6) hepatocellular

carcinoma. Patients in each health state were identified using diagnostic

and procedure codes, and their utilization was tracked during their time in

that health state. To estimate costs, we used reimbursed amounts and

adjusted to year 2000 US$.

Results: Average annual costs for patients in each health state were as

follows: CHB, $761; compensated cirrhosis, $227; decompensated cirrhosis,

$11,459; liver transplant, $86,552; transplant care >12 months following

transplant, $12,560; and hepatocellular carcinoma, $7,533. Medications

contributed the largest proportion of costs in CHB and compensated cirrhosis

disease states, while hospitalizations were the largest cost component in

the other health states.

Conclusions: This analysis provides estimates of the annual costs of

complications of hepatitis B infection in the United States. The most

progressive health states were associated with significantly higher costs.

[Guest guest]

Cost of Chronic Hepatitis B Infection in the United States.

Journal of Clinical Gastroenterology. Chronic Hepatitis B from a Global

Perspective: Epidemiology and Costs of Illness. 38(10) Supplement

3:S144-S147, November/December 2004.

Lee, Todd A. PharmD, PhD *+++; Veenstra, L. PharmD, PhD ; Hloeje,

Uchenna H. MD, MPH [P]; Sullivan, D. PhD

Abstract:

Goals: To estimate the direct medical costs associated with chronic

hepatitis B (CHB) infection in the United States.

Background: Approximately 240,000 new cases of hepatitis B infection occur

annually in the United States. There are estimated to be 1.25 million

sufferers of CHB in the United States. However, the economic impact of these

infections has not been well studied.

Study: We conducted a retrospective cohort analysis using administrative

healthcare claims data to estimate costs for six health states associated

with CHB infection. The six states were as follows: 1) CHB, 2) compensated

cirrhosis, 3) decompensated cirrhosis, 4) liver transplantation, 5)

transplant care >12 months following transplant, and 6) hepatocellular

carcinoma. Patients in each health state were identified using diagnostic

and procedure codes, and their utilization was tracked during their time in

that health state. To estimate costs, we used reimbursed amounts and

adjusted to year 2000 US$.

Results: Average annual costs for patients in each health state were as

follows: CHB, $761; compensated cirrhosis, $227; decompensated cirrhosis,

$11,459; liver transplant, $86,552; transplant care >12 months following

transplant, $12,560; and hepatocellular carcinoma, $7,533. Medications

contributed the largest proportion of costs in CHB and compensated cirrhosis

disease states, while hospitalizations were the largest cost component in

the other health states.

Conclusions: This analysis provides estimates of the annual costs of

complications of hepatitis B infection in the United States. The most

progressive health states were associated with significantly higher costs.

[Guest guest]

Cost of Chronic Hepatitis B Infection in the United States.

Journal of Clinical Gastroenterology. Chronic Hepatitis B from a Global

Perspective: Epidemiology and Costs of Illness. 38(10) Supplement

3:S144-S147, November/December 2004.

Lee, Todd A. PharmD, PhD *+++; Veenstra, L. PharmD, PhD ; Hloeje,

Uchenna H. MD, MPH [P]; Sullivan, D. PhD

Abstract:

Goals: To estimate the direct medical costs associated with chronic

hepatitis B (CHB) infection in the United States.

Background: Approximately 240,000 new cases of hepatitis B infection occur

annually in the United States. There are estimated to be 1.25 million

sufferers of CHB in the United States. However, the economic impact of these

infections has not been well studied.

Study: We conducted a retrospective cohort analysis using administrative

healthcare claims data to estimate costs for six health states associated

with CHB infection. The six states were as follows: 1) CHB, 2) compensated

cirrhosis, 3) decompensated cirrhosis, 4) liver transplantation, 5)

transplant care >12 months following transplant, and 6) hepatocellular

carcinoma. Patients in each health state were identified using diagnostic

and procedure codes, and their utilization was tracked during their time in

that health state. To estimate costs, we used reimbursed amounts and

adjusted to year 2000 US$.

Results: Average annual costs for patients in each health state were as

follows: CHB, $761; compensated cirrhosis, $227; decompensated cirrhosis,

$11,459; liver transplant, $86,552; transplant care >12 months following

transplant, $12,560; and hepatocellular carcinoma, $7,533. Medications

contributed the largest proportion of costs in CHB and compensated cirrhosis

disease states, while hospitalizations were the largest cost component in

the other health states.

Conclusions: This analysis provides estimates of the annual costs of

complications of hepatitis B infection in the United States. The most

progressive health states were associated with significantly higher costs.

[Guest guest]

Cost of Chronic Hepatitis B Infection in the United States.

Journal of Clinical Gastroenterology. Chronic Hepatitis B from a Global

Perspective: Epidemiology and Costs of Illness. 38(10) Supplement

3:S144-S147, November/December 2004.

Lee, Todd A. PharmD, PhD *+++; Veenstra, L. PharmD, PhD ; Hloeje,

Uchenna H. MD, MPH [P]; Sullivan, D. PhD

Abstract:

Goals: To estimate the direct medical costs associated with chronic

hepatitis B (CHB) infection in the United States.

Background: Approximately 240,000 new cases of hepatitis B infection occur

annually in the United States. There are estimated to be 1.25 million

sufferers of CHB in the United States. However, the economic impact of these

infections has not been well studied.

Study: We conducted a retrospective cohort analysis using administrative

healthcare claims data to estimate costs for six health states associated

with CHB infection. The six states were as follows: 1) CHB, 2) compensated

cirrhosis, 3) decompensated cirrhosis, 4) liver transplantation, 5)

transplant care >12 months following transplant, and 6) hepatocellular

carcinoma. Patients in each health state were identified using diagnostic

and procedure codes, and their utilization was tracked during their time in

that health state. To estimate costs, we used reimbursed amounts and

adjusted to year 2000 US$.

Results: Average annual costs for patients in each health state were as

follows: CHB, $761; compensated cirrhosis, $227; decompensated cirrhosis,

$11,459; liver transplant, $86,552; transplant care >12 months following

transplant, $12,560; and hepatocellular carcinoma, $7,533. Medications

contributed the largest proportion of costs in CHB and compensated cirrhosis

disease states, while hospitalizations were the largest cost component in

the other health states.

Conclusions: This analysis provides estimates of the annual costs of

complications of hepatitis B infection in the United States. The most

progressive health states were associated with significantly higher costs.